Need Help? Talk to an Expert +1 (408) 836-7136

Home

>

ipos-overview

Ipos overview

Drugs Made In America Acquisition II Corp. (DMIIU)


Company Overview

Proposed Symbol DMIIU
Company Name Drugs Made In America Acquisition II Corp.
Exchange NASDAQ Global
Share Price $10.00
Employees 2 (as of 09/25/2025)
Status Priced
Shares Offered 50,000,000
Offer amount $500,000,000
Shares Over Alloted
Company Address 1 EAST BROWARD BOULEVARD SUITE 700 FORT LAUDERDALE FL 33301
Company Phone 954-870-3104
Company Website
CEO Lynn Stockwell
State of Inc
Fiscal Year End 12-31
Total Offering Expense $750,000.00
Shareholder Shares Offered
Shares Outstanding 63,700,000
Lockup Period (days) 180
Lockup Expiration 2026-03-24 00:00:00
Quiet Period Expiration 2025-11-04 00:00:00
CIK 0002040475
DealId 1342770-114639

Company Description

Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success. Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders. --- Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.